Alpha 2.0

» Articles » PMID: 24249594

Fluorescently Labeled Chimeric Anti-CEA Antibody Improves Detection and Resection of Human Colon Cancer in a Patient-derived Orthotopic Xenograft (PDOX) Nude Mouse Model

Overview

Overview

Journal J Surg Oncol

Specialties General Surgery
Oncology

Date 2013 Nov 20

PMID 24249594

Citations 82

Authors

Authors

Cristina A Metildi

Sharmeela Kaushal

George A Luiken

Mark A Talamini

Robert M Hoffman

Michael Bouvet

Affiliations

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: The aim of this study was to evaluate a new fluorescently labeled chimeric anti-CEA antibody for improved detection and resection of colon cancer.

Methods: Frozen tumor and normal human tissue samples were stained with chimeric and mouse antibody-fluorophore conjugates for comparison. Mice with patient-derived orthotopic xenografts (PDOX) of colon cancer underwent fluorescence-guided surgery (FGS) or bright-light surgery (BLS) 24 hr after tail vein injection of fluorophore-conjugated chimeric anti-CEA antibody. Resection completeness was assessed using postoperative images. Mice were followed for 6 months for recurrence.

Results: The fluorophore conjugation efficiency (dye/mole ratio) improved from 3-4 to >5.5 with the chimeric CEA antibody compared to mouse anti-CEA antibody. CEA-expressing tumors labeled with chimeric CEA antibody provided a brighter fluorescence signal on frozen human tumor tissues (P = 0.046) and demonstrated consistently lower fluorescence signals in normal human tissues compared to mouse antibody. Chimeric CEA antibody accurately labeled PDOX colon cancer in nude mice, enabling improved detection of tumor margins for more effective FGS. The R0 resection rate increased from 86% to 96% with FGS compared to BLS.

Conclusion: Improved conjugating efficiency and labeling with chimeric fluorophore-conjugated antibody resulted in better detection and resection of human colon cancer in an orthotopic mouse model.

Citing Articles

Potential Probes for Targeted Intraoperative Fluorescence Imaging in Gastric Cancer.

Martinelli S, Fortuna L, Coratti F, Passagnoli F, Amedei A, Cianchi F Cancers (Basel). 2025; 16(24.

PMID: 39766041 PMC: 11675003. DOI: 10.3390/cancers16244141.

Global trends in the application of fluorescence imaging in pancreatic diseases: a bibliometric and knowledge graph analysis.

Luo Q, Teng X, Dai M, Yang J, Cheng W, Chen K Front Oncol. 2024; 14:1383798.

PMID: 39099697 PMC: 11294181. DOI: 10.3389/fonc.2024.1383798.

An Orthotopic Patient-Derived Xenograft (PDX) Model Allows the Analysis of Metastasis-Associated Features in Colorectal Cancer.

De Angelis M, Francescangeli F, Nicolazzo C, Xhelili E, La Torre F, Colace L Front Oncol. 2022; 12:869485.

PMID: 35837106 PMC: 9275818. DOI: 10.3389/fonc.2022.869485.

Patient-derived models of brain metastases recapitulate human disseminated disease.

Faria C, Cascao R, Custodia C, Paisana E, Carvalho T, Pereira P Cell Rep Med. 2022; 3(5):100623.

PMID: 35584628 PMC: 9133464. DOI: 10.1016/j.xcrm.2022.100623.

Fluorescence Molecular Targeting of Colon Cancer to Visualize the Invisible.

Lwin T, Turner M, Amirfakhri S, Nishino H, Hoffman R, Bouvet M Cells. 2022; 11(2).

PMID: 35053365 PMC: 8773892. DOI: 10.3390/cells11020249.

References

1.

Bressler B, Paszat L, Vinden C, Li C, He J, Rabeneck L . Colonoscopic miss rates for right-sided colon cancer: a population-based analysis. Gastroenterology. 2004; 127(2):452-6. DOI: 10.1053/j.gastro.2004.05.032. View

2.

Campos F, Calijuri-Hamra M, Imperiale A, Kiss D, Nahas S, Cecconello I . Locally advanced colorectal cancer: results of surgical treatment and prognostic factors. Arq Gastroenterol. 2011; 48(4):270-5. DOI: 10.1590/s0004-28032011000400010. View

3.

Sharma S, Camci C, Jabbour N . Management of hepatic metastasis from colorectal cancers: an update. J Hepatobiliary Pancreat Surg. 2008; 15(6):570-80. DOI: 10.1007/s00534-008-1350-x. View

4.

Yedibela S, Klein P, Feuchter K, Hoffmann M, Meyer T, Papadopoulos T . Surgical management of pulmonary metastases from colorectal cancer in 153 patients. Ann Surg Oncol. 2006; 13(11):1538-44. DOI: 10.1245/s10434-006-9100-2. View

5.

Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S . Standardized surgery for colonic cancer: complete mesocolic excision and central ligation--technical notes and outcome. Colorectal Dis. 2008; 11(4):354-64. DOI: 10.1111/j.1463-1318.2008.01735.x. View

6.

Ho M, Royston I, Beck A . 2nd PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA. MAbs. 2012; 4(5):562-70. PMC: 3499296. DOI: 10.4161/mabs.21521. View

7.

Metildi C, Kaushal S, Hardamon C, Snyder C, Pu M, Messer K . Fluorescence-guided surgery allows for more complete resection of pancreatic cancer, resulting in longer disease-free survival compared with standard surgery in orthotopic mouse models. J Am Coll Surg. 2012; 215(1):126-35. PMC: 3383387. DOI: 10.1016/j.jamcollsurg.2012.02.021. View

8.

Tran Cao H, Kaushal S, Metildi C, Menen R, Lee C, Snyder C . Tumor-specific fluorescence antibody imaging enables accurate staging laparoscopy in an orthotopic model of pancreatic cancer. Hepatogastroenterology. 2012; 59(118):1994-9. PMC: 4096574. DOI: 10.5754/hge11836. View

9.

Tran Cao H, Kaushal S, Lee C, Snyder C, Thompson K, Horgan S . Fluorescence laparoscopy imaging of pancreatic tumor progression in an orthotopic mouse model. Surg Endosc. 2010; 25(1):48-54. PMC: 3003784. DOI: 10.1007/s00464-010-1127-6. View

10.

Nelson A, Dhimolea E, Reichert J . Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010; 9(10):767-74. DOI: 10.1038/nrd3229. View

11.

Fu X, Besterman J, Monosov A, Hoffman R . Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci U S A. 1991; 88(20):9345-9. PMC: 52711. DOI: 10.1073/pnas.88.20.9345. View

12.

Manfredi S, Benhamiche A, Meny B, Cheynel N, Rat P, Faivre J . Population-based study of factors influencing occurrence and prognosis of local recurrence after surgery for rectal cancer. Br J Surg. 2001; 88(9):1221-7. DOI: 10.1046/j.0007-1323.2001.01861.x. View

13.

Bouvet M, Hoffman R . Glowing tumors make for better detection and resection. Sci Transl Med. 2011; 3(110):110fs10. DOI: 10.1126/scitranslmed.3003375. View

14.

Abulafi A, Williams N . Local recurrence of colorectal cancer: the problem, mechanisms, management and adjuvant therapy. Br J Surg. 1994; 81(1):7-19. DOI: 10.1002/bjs.1800810106. View

15.

Ruo L, Guillem J . Surgical management of primary colorectal cancer. Surg Oncol. 2000; 7(3-4):153-63. DOI: 10.1016/s0960-7404(99)00033-x. View

16.

Reichert J, Dhimolea E . The future of antibodies as cancer drugs. Drug Discov Today. 2012; 17(17-18):954-63. DOI: 10.1016/j.drudis.2012.04.006. View

17.

Bokey E, Chapuis P, Dent O, Mander B, Bissett I, Newland R . Surgical technique and survival in patients having a curative resection for colon cancer. Dis Colon Rectum. 2003; 46(7):860-6. DOI: 10.1007/s10350-004-6673-3. View

18.

Verwaal V, van Ruth S, de Bree E, van Sloothen G, van Tinteren H, Boot H . Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003; 21(20):3737-43. DOI: 10.1200/JCO.2003.04.187. View

19.

Sadeghi B, Arvieux C, Glehen O, Beaujard A, Rivoire M, Baulieux J . Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000; 88(2):358-63. DOI: 10.1002/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o. View

20.

Beck A, Wurch T, Bailly C, Corvaia N . Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010; 10(5):345-52. DOI: 10.1038/nri2747. View